Bayer’s bid to maintain its lead in the anti-vascular endothelial growth factor (VEGF) eye disease space has received a boost with a fresh approval in Europe that extends the intervals between injections for the high dose of its blockbuster Eylea.
Key Takeaways
- The European Commission has approved Eylea 8mg with an extended treatment interval of up to six months for wet AMD and DME.
The European Commission has granted a label extension for Eylea 8mg (aflibercept), or Eylea HD, with extended treatment intervals of...